DE2414219A1 - Mittel zur immunoregulation von pollenallergie - Google Patents
Mittel zur immunoregulation von pollenallergieInfo
- Publication number
- DE2414219A1 DE2414219A1 DE19742414219 DE2414219A DE2414219A1 DE 2414219 A1 DE2414219 A1 DE 2414219A1 DE 19742414219 DE19742414219 DE 19742414219 DE 2414219 A DE2414219 A DE 2414219A DE 2414219 A1 DE2414219 A1 DE 2414219A1
- Authority
- DE
- Germany
- Prior art keywords
- allergen
- ragwort
- specific
- igg
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 title claims description 9
- 206010048908 Seasonal allergy Diseases 0.000 title claims description 7
- 201000004338 pollen allergy Diseases 0.000 title claims description 7
- 230000007365 immunoregulation Effects 0.000 title description 6
- 239000013566 allergen Substances 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 208000010668 atopic eczema Diseases 0.000 claims description 20
- 230000000172 allergic effect Effects 0.000 claims description 19
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 17
- 102000006395 Globulins Human genes 0.000 claims description 14
- 108010044091 Globulins Proteins 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000013573 pollen allergen Substances 0.000 claims description 6
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 claims description 5
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 claims description 5
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 claims description 5
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000010755 BS 2869 Class G Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000409199 Packera Species 0.000 claims 3
- 108010094139 tumor-globulin Proteins 0.000 claims 1
- 240000003705 Senecio vulgaris Species 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000000586 desensitisation Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 208000026935 allergic disease Diseases 0.000 description 13
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 12
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 235000003484 annual ragweed Nutrition 0.000 description 9
- 235000006263 bur ragweed Nutrition 0.000 description 9
- 235000003488 common ragweed Nutrition 0.000 description 9
- 235000009736 ragweed Nutrition 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010040914 Skin reaction Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000035483 skin reaction Effects 0.000 description 5
- 231100000430 skin reaction Toxicity 0.000 description 5
- 231100000121 skin sensitizing Toxicity 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000002132 Beaucarnea recurvata Species 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 241000245643 Koeleria Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- 244000124765 Salsola kali Species 0.000 description 1
- 235000007658 Salsola kali Nutrition 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 240000002751 Sideroxylon obovatum Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 244000152045 Themeda triandra Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34475873A | 1973-03-26 | 1973-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2414219A1 true DE2414219A1 (de) | 1974-10-10 |
Family
ID=23351904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742414219 Pending DE2414219A1 (de) | 1973-03-26 | 1974-03-25 | Mittel zur immunoregulation von pollenallergie |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE812801A (enExample) |
| DE (1) | DE2414219A1 (enExample) |
| FR (1) | FR2223003B1 (enExample) |
| GB (1) | GB1422760A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2846412A1 (de) * | 1978-10-25 | 1980-05-08 | Behringwerke Ag | Mittel zur behandlung allergischer reaktionen |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8406560D0 (en) * | 1984-03-13 | 1984-04-18 | Central Lab Of The Blood Donor | Organic compounds |
| KR20070108320A (ko) * | 2006-03-20 | 2007-11-09 | 전숙영 | 알레르기질환 및 자가면역질환의 치료를 위한 약학적조성물, 그의 용도 및 알레르기질환 및 자가면역질환의치료방법 |
-
1974
- 1974-03-25 FR FR7410070A patent/FR2223003B1/fr not_active Expired
- 1974-03-25 DE DE19742414219 patent/DE2414219A1/de active Pending
- 1974-03-25 GB GB1320574A patent/GB1422760A/en not_active Expired
- 1974-03-25 BE BE142431A patent/BE812801A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2846412A1 (de) * | 1978-10-25 | 1980-05-08 | Behringwerke Ag | Mittel zur behandlung allergischer reaktionen |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2223003A1 (enExample) | 1974-10-25 |
| FR2223003B1 (enExample) | 1976-12-10 |
| GB1422760A (en) | 1976-01-28 |
| BE812801A (fr) | 1974-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2804457C2 (de) | Immunsuppressive Mittel | |
| Evans et al. | Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. | |
| DE69424362T2 (de) | Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens | |
| DE60032250T2 (de) | Behandlung von Allergien | |
| DE69230733T3 (de) | Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen | |
| DE69724970T2 (de) | Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a | |
| DE69511245T2 (de) | Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a | |
| Warren et al. | Cystic fibrosis—immunological reactions to A. fumigatus and common allergens | |
| DE69127694T2 (de) | Herstellung und verwendung von transfer-faktor | |
| DE112011102362T5 (de) | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen | |
| CH672987A5 (enExample) | ||
| DE3850433T2 (de) | Allergiebehandlung und Zusammensetzung dafür. | |
| NO144056B (no) | Innretning for kunstig vanning av blomsterbed, hager etc. | |
| EP0496839A1 (de) | Impfstoff und immunserum gegen drogen. | |
| DE2633932A1 (de) | Verfahren zur gewinnung eines humanen anti-hb tief s -gamma-globulins | |
| DE2603321A1 (de) | Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser | |
| DE2827027A1 (de) | Gefriergetrocknetes natives gammaglobulin-praeparat zur intravenoesen verabreichung und verfahren zu seiner herstellung | |
| Kawano et al. | A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis | |
| EP0010309B2 (de) | Mittel zur Behandlung allergischer Reaktionen | |
| Patterson et al. | The passive transfer to normal dogs of skin reactivity, asthma and anaphylaxis from a dog with spontaneous ragweed pollen hypersensitivity | |
| DE112011102356T5 (de) | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen | |
| Pinnas et al. | Harvester ant sensitivity: in vitro and in vivo studies using whole body extracts and venom | |
| DE3750235T2 (de) | Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen. | |
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE69535460T2 (de) | Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |